Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Phase 3 Completed 354 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)

Timeline

Start: 2021-10-06
Primary completion: 2025-04-11
Completion: 2026-02-18

Publications

Stone JH, Venhoff N, Buttgereit F, Dejaco C, Schmidt WA, Spiera R, Blanco R, Rubbert-Roth A, Von Frenckell C, Blockmans D, Terrier B, Tracey G, Hauge EM, Keyport MP, Ng J, Hiremath R, Fu R, Cho G, Bacher G, Thiel J, Mendelson MH. Secukinumab for Giant Cell Arteritis. NEJM Evid. 2026 Jul;5(7):EVIDoa2600112. doi: 10.1056/EVIDoa2600112. Epub 2026 Jun 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Summary

Timeline

Publications

Drugs

Indications